News
Novo Nordisk Names Maziar Mike Doustdar as President and Chief Executive Officer
Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief executive officer (CEO). Jørgensen will step down from his current role serving as president and CEO on the same day Doustdar is expected to take over.
After the surprise departure of longtime CEO Lars Fruergaard Jørgensen in May, Danish pharma giant Novo Nordisk didn’t take ...
Professor Lene Oddershede Chief Scientific Officer, Planetary Science & Technology at the Novo Nordisk Foundation talks about the applications of quantum computing at the tech disruptors podcast. She ...
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
Barchart on MSN12h
Should You Buy the Post-Earnings Plunge in Novo Nordisk Stock or Stay Far, Far Away?Novo Nordisk (NVO) stock shed over 21% on Tuesday after the Danish pharmaceutical giant slashed its guidance for the second time this year, leaving investors questioning whether the obesity drug ...
Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO. Doustdar will succeed Lars Fruergaard Jørgensen, whose surprise abdication was ...
Bagsværd, Denmark, 29 July 2025 - Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds La ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback